Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Fig. 3

Proportions of patients reporting changes from baseline to week 52 meeting or exceeding MCID. MCIDs are based on patients with RA and SLE, and data are shown for PROs (a) and SF-36 domain scores (b) and proportions of patients reporting scores meeting or exceeding A/G-matched normative values in PROs (c) and SF-36 domain scores (d) at week 52. A/G age/gender, BL baseline, BP bodily pain, FACIT Functional Assessment of Chronic Illness Therapy, GH general health, MCID minimal clinically important difference, MCS Mental Component Summary, MH mental health, PBO placebo, PCS Physical Component Summary, PF physical function, Pred-26 26-week prednisone taper, Pred-52 52-week prednisone taper, PROs patient-reported outcomes, QW every week, RA rheumatoid arthritis, RE role emotional, RP role physical, SF social function, SF-36 36-Item Short-Form Health Survey, SLE systemic lupus erythematosus, TCZ tocilizumab, VT vitality

Back to article page